A Single Dose, Dose Escalation Clinical Trial on the Safety, Tolerability and Efficacy of Lyophilized Powder for Inhalation of Recombinant Human Keratinocyte Growth Factor-2 (Rh-KGF-2) in The Treatment of Patients With Acute Respiratory Distress Syndrome
This study is a randomized, blank-controlled, open-label, single-dose, dose-escalation clinical study of rhKGF-2 in patients with ARDS.
The trial is designed with three dose groups (5 mg, 10 mg, and 15 mg), which will be escalated sequentially from the lowest dose group to the highest dose group. Each dose group will enroll 8 subjects, randomized in a 6:2 ratio according to the order of enrollment, to receive either the corresponding dose of rhKGF-2 (6 subjects) or serve as a blank control (2 subjects). Each subject will receive a single dose, administered once via a disposable bronchoscopic catheter.
All subjects will receive the trial intervention on top of standard ARDS treatment (see Concomitant Medications for details). Following the completion of drug administration, subjects will enter a 28-day follow-up period. Outcome measures include adverse events (AE), vital signs, laboratory parameters, oxygenation index (PFR), chest imaging changes, etc., to evaluate the safety, tolerability, and efficacy of the treatment.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Tidlig fase 1
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Yi Wei
- Telefonnummer: +86 18872984075
- E-post: yiwei4075@163.com
Studiesteder
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200000
- Rekruttering
- ShanghaiZhongshan
-
Ta kontakt med:
- Yi Wei
- Telefonnummer: +86 18872984075
- E-post: yiwei4075@163.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Aged ≥18 years and <80 years, male or female.
- Definite diagnosis of acute respiratory distress syndrome (ARDS) according to the Berlin Definition.
- Patients with PaO₂/FiO₂ < 200 mmHg and receiving invasive mechanical ventilation via endotracheal intubation.
- Diagnosis of ARDS confirmed no more than 72 hours prior to enrollment.
- No plan for parenthood within 1 year and agree to take effective contraceptive measures during the study period. Female participants of childbearing potential must have a negative serum pregnancy test.
The subject fully understands the purpose of the study, as well as the nature, methods, and potential reactions of the investigational drug. The subject voluntarily signs the informed consent form to participate in the study and agrees to comply with the requirements of the study protocol. If the subject is unable to provide consent or has limited capacity to consent, consent must be obtained from the subject's legal guardian.
-
Exclusion Criteria:
- Use of inhaled pulmonary vasodilators (e.g., nitric oxide or prostaglandins).
- Current receipt or planned receipt of extracorporeal membrane oxygenation (ECMO) during the study period.
- Expected survival < 3 months due to causes other than respiratory failure.
- Cerebrovascular or cardiovascular events within 3 months prior to study drug administration, including unstable angina, congestive heart failure, myocardial infarction within the past 12 months, hemodynamic instability, known left ventricular ejection fraction (LVEF) < 40%, or clinically significant arrhythmia or conduction abnormality.
- Inability to tolerate single-use bronchoscopic imaging catheter examination, including but not limited to the following: active massive hemoptysis; severe hypertension and arrhythmia; myocardial infarction or unstable angina within 4-6 weeks prior to screening; severe cardiac dysfunction; uncorrectable bleeding tendency (platelet count < 60 × 10⁹/L), such as severe coagulation disorders, uremia, or severe pulmonary hypertension; severe superior vena cava syndrome; suspected aortic aneurysm; multiple pulmonary bullae.
- History of severe allergic reaction, or known allergy or hypersensitivity to any component of the investigational product.
- Breastfeeding or pregnant women.
- Participation in any drug clinical trial within 3 months prior to enrollment.
- Any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in this study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: 5 mg rhKGF-2
|
The investigational drug will be reconstituted with water for injection to a concentration of 1 mg/mL, and then administered via a single-use bronchoscopic imaging catheter.
|
|
Ingen inngripen: Blank Control for 5 mg Cohort
|
|
|
Eksperimentell: 10 mg rhKGF-2
|
The investigational drug will be reconstituted with water for injection to a concentration of 1 mg/mL, and then administered via a single-use bronchoscopic imaging catheter.
|
|
Ingen inngripen: Blank Control for 10 mg Cohort
|
|
|
Eksperimentell: 15 mg rhKGF-2
|
The investigational drug will be reconstituted with water for injection to a concentration of 1 mg/mL, and then administered via a single-use bronchoscopic imaging catheter.
|
|
Ingen inngripen: Blank Control for 15 mg Cohort
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of adverse events (AE) and incidence of adverse drug reactions (ADR);
Tidsramme: At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
|
At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
|
|
|
Incidence of serious adverse events (SAE)
Tidsramme: At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
|
At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
|
|
|
Various laboratory test parameters:White blood cell (WBC) count
Tidsramme: At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
|
Unit of measure: 3.5 - 9.5 × 10^9/L
|
At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
|
|
Various Laboratory test parameters: Serum creatinine (Cr) level
Tidsramme: At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
|
Unit of measure: 44 -115 μmol/L
|
At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
|
|
Various laboratory test parameters: Total Bilirubin
Tidsramme: At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
|
Unit of measure: 3.4-20.4
umol /L
|
At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
|
|
Incidence of airway spasm (increased airway resistance) caused by local drug stimulation
Tidsramme: At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
|
At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Improvement rate of oxygenation indexPaO₂/FiO₂ ratio (PFR)
Tidsramme: at Day 3 and Day 7
|
at Day 3 and Day 7
|
|
|
PaO₂/FiO₂ ratio (PFR) and its change from baseline
Tidsramme: at Day 3, Day 5, and Day 7
|
at Day 3, Day 5, and Day 7
|
|
|
Number of days from baseline to first PaO₂/FiO₂ ratio (PFR) > 300 mmHg or liberation from mechanical ventilation for at least 12 consecutive hours
Tidsramme: From baseline to first PFR > 300 mmHg or liberation from mechanical ventilation for at least 12 consecutive hours
|
From baseline to first PFR > 300 mmHg or liberation from mechanical ventilation for at least 12 consecutive hours
|
|
|
Change from baseline in the Murray Lung Injury Score(LIS).
Tidsramme: at Day 7
|
Score (scale range: 0-4; higher scores indicate more severe lung injury)
|
at Day 7
|
|
Change from baseline in Radiographic Assessment of Lung Edema (RALE) score;
Tidsramme: at Day 3, Day 7, Day 14, and Day 28
|
Score (scale range: 0-48; higher scores indicate a worse outcome);
|
at Day 3, Day 7, Day 14, and Day 28
|
|
Proportion of patients with improvement in ARDS severity grade
Tidsramme: at Day 7 and Day 14
|
at Day 7 and Day 14
|
|
|
Proportion of patients with progression in ARDS severity grade
Tidsramme: at Day 7 and Day 14
|
at Day 7 and Day 14
|
|
|
All-cause mortality
Tidsramme: at Day 28
|
at Day 28
|
|
|
Systemic evaluation measures: Ventilator-free days at Day 28
Tidsramme: at Day 28
|
Ventilator-free days at Day 28 (unit: days; higher scores indicate a better outcome).
|
at Day 28
|
|
Systemic evaluation measures: Non-ICU hospital stay days at Day 28
Tidsramme: at Day 28.
|
Non-ICU hospital stay days at Day 28 (unit: days; higher scores indicate a better outcome as applicable).
|
at Day 28.
|
|
Systemic evaluation measures: Non-hospitalization days at Day 28
Tidsramme: at Day 28
|
Non-hospitalization days at Day 28 (unit: days; higher scores indicate a better outcome).
|
at Day 28
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Studieleder: Yuanlin Song, Shanghai Zhongshan Hospital
- Hovedetterforsker: Jing Bi, Shanghai Zhongshan Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer
- Sykdommer i immunsystemet
- Sykdommer i luftveiene
- Neoplasmer etter histologisk type
- Lungesykdommer
- Lymfesykdommer
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Lymfom, Non-Hodgkin
- Lymfom
- Lungeskade
- Hemic og lymfatiske sykdommer
- Lymfom, follikulær
- Akutt lungeskade
- Sirkulasjons- og luftveisfysiologiske fenomener
- Åndedrettsmekanikk
- Respirasjon
- Luftveisfysiologiske fenomener
- Innånding
Andre studie-ID-numre
Andre studie-ID-numre
- B2026-113R
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
Tilgangskriterier for IPD-deling
IPD-deling Støtteinformasjonstype
- ICF
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .